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EZH2 knockdown suppresses the growth and
invasion of human inflammatory breast cancer
cells
Zhaomei Mu1,2†, Hua Li3†, Sandra V Fernandez1,2, Katherine R Alpaugh2, Rugang Zhang3 and
Massimo Cristofanilli1,2*

Abstract
Introduction: Inflammatory breast cancer (IBC) is the most metastatic variant of breast cancer with the poorest survival
in all types of breast cancer patients and presently therapeutic targets for IBC are very limited. Enhancer of zeste homolog
2 (EZH2) is frequently expressed in human IBC and its expression positively correlates with worse clinical outcome.
However, the molecular basis for EZH2 promoting IBC has not been explored. Here, we investigated the functional role of
EZH2 in IBC cells by examining the effects of its knockdown on the formation of tumor spheroids and invasion of these
cells in vitro and in vivo in an orthotopic xenograft model.
Methods: SUM149 and a new IBC cell line-FC-IBC-02 derived from pleural effusion fluid of an IBC patient were used in
this study. Specific knockdown of EZH2 was performed using short hairpin RNA (shRNA) specific to the human EZH2
gene. Cell growth and the formation of tumor spheroids were examined in vitro. The effects of EZH2 knockdown on IBC
cell migration and invasion were examined by a Boyden chamber assay. For the in vivo tumor growth studies, IBC cells
were orthotopically transplanted into the mammary fat pads of immunodeficient mice.
Results: The results showed that EZH2 is expressed at higher levels in human IBC cell lines compared with normal
human mammary epithelial cells, and the knockdown of EZH2 expression significantly suppressed cell growth and tumor
spheroid formation of human IBC cells in vitro. In addition, EZH2 knockdown inhibited the migration and invasion of IBC
cells. Significantly, EZH2 knockdown suppressed the angiogenesis and tumor growth of IBC cells in vivo.
Conclusions: Our results provide direct evidence that EZH2 is critical for the formation of tumor spheroids and invasion
of human IBC cells and could be a potential target for developing novel therapeutic strategies for
human IBC.
Keywords: Inflammatory breast cancer, EZH2, Cancer stem cell, Tumor spheroid formation

Introduction
Inflammatory breast cancer (IBC) is the most aggressive
variant of locally advanced breast cancer, and currently accounts for 1% to 6% of all breast cancer patients in the
United States [1,2]. IBC has shown the capacity to spread
early, primarily through lymphatic channels and secondarily through blood vessels causing the specific inflammatory
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signs, such as diffuse erythema, edema, tenderness, and
warmth [3,4]. IBC is difficult to detect as it does not
present as a lump but rather occurs as tumor emboli.
These IBC tumor emboli are non-adherent cell clusters
that rapidly spread by a continuous passive dissemination,
thus favoring both distal metastasis and local recurrence
[5]. Primary treatment of patients with IBC is typically
multimodal involving neoadjuvant combination chemotherapy followed by surgery, adjuvant chemotherapy, or
radiotherapy [6]. Epidermal growth factor receptor (EGFR)
and HER2 receptor overexpression have been demonstrated as prognosis and predictive factors in IBC [7,8].
Anti-HER2 therapies have shown benefit in IBC patients
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with HER2 amplification, which accounts for approximately 40% of IBC [9]. However, therapeutic options for
patients with estrogen-receptor negative (ER-) and HER2
non-amplified IBC patients are very limited. Notably, IBCs
are predominantly basal-like or triple-negative as demonstrated by the ER-negative, progesterone receptor (PgR)negative and HER2 non-amplified status [10]. Thus, there
is an urgent need to identify a new therapeutic strategy for
IBC, particularly for triple-negative IBC.
Enhancer of zeste homolog 2 (EZH2) is the catalytic
subunit of polycomb repressive complex 2 (PRC2), while
noncatalytic subunits suppressor of zeste 12 (SUZ12) and
embryonic ectoderm development (EED) are also necessary for its optimal activity [11]. EZH2 is upregulated in
several types of cancers and has been implicated in regulating multiple cellular processes such as proliferation,
differentiation, cell cycle, apoptosis, invasion, and selfrenewal [12,13]. For example, EZH2 is often expressed at
higher levels in breast cancer and its overexpression correlates with aggressiveness and poor prognosis [14-20]. We
have recently shown that EZH2 is often expressed in IBCs
and is a marker for poor prognosis in these patients [21].
Interestingly, there is a significant positive correlation between EZH2 expression and triple-negative status [21].
Strikingly, all triple-negative tumors were found positive
for EZH2 expression. This expression pattern raises the
possibility that EZH2 could represent a potential therapeutic target in IBC and, in particular, in triple-negative
IBC that currently has very limited treatment options.
The clinical symptoms and biological features of IBC are
very distinct from other types of breast cancer. Currently
there are few human IBC cell lines available for studying
this complex disease. We have recently developed a new
IBC cell line FC-IBC-02 that was derived from the pleural
effusion fluid of a woman with metastatic secondary IBC
[22]. FC-IBC-02 cells are triple-negative, and form tumor
spheroids in suspension culture, a characteristic of cancer
stem cells, and recapitulate the tumor emboli, a signature
sign of IBC in humans in vivo xenograft models. FC-IBC02 cells also expressed some cancer stem cell (CSC)
markers. The CSC population is also thought to play a key
role in breast cancer development, progression, and relapse
following treatments [23-27]. Overexpression of EZH2
promotes self-renewal of breast tumor initiating cells [28].
Interestingly, in embryonic stem cells, EZH2 directly controls the expression of Oct4, a stem cell marker, to regulate
the stem cell equilibrium [29]. Together, these evidences
suggest that EZH2 may regulate cancer stem/initiating cell
equilibrium in IBC.
In the present study, we examined the expression of
the components of PRC2 in human IBC cells, as well as
the effects of EZH2 knockdown on the formation of
tumor spheroids, invasion and tumor growth of human
IBC cells.

Page 2 of 9

Methods and materials
Cell culture

SUM149 and SUM190 cells were cultured in Ham’s F-12
media supplemented with 10% fetal bovine serum (FBS),
1 μg/ml hydrocortisone, 5 μg/ml insulin and antibioticantimycotic. Primary human mammary epithelial cells
(HMEC) were isolated and cultured as previously described [30]. The protocol was approved by institutional
review board (IRB) of Fox Chase Cancer Center (FCCC).
The FC-IBC-02 tumor cells were derived from primary
human breast cancer cells isolated from pleural effusion
fluid of an IBC patient. Human samples used in this
study were acquired with approval of the Fox Chase
Cancer Center’s Institutional Review Board. Importantly,
written informed consent form was obtained from each
participant. FC-IBC-02 cells were cultured in Ham’s F12
with 10% FBS and 5 ml Insulin/L with 100 μg/L hydrocortisone and antibiotic-antimycotic. FC-IBC-02 cells
grow as both adherent (FC-IBC-02A) and suspension
(FC-IBC-02S) populations.

EZH2 knockdown and lentivirus infection

The sense sequences of 2 individual 21-nucleotide shRNAs
targeting the human EZH2 genes (shEZH2) were previously described [31]. Lentivirus packaging was performed
using ViraPower system (Invitrogen) according to the
manufacturer’s instruction as previously described [31].
Briefly, the cells were infected with lentivirus expressing
shEZH2 or vector control. The infected cells were drug
selected with 2 μg/mL of puromycin to eliminate noninfected cells.

Antibodies and immunoblot

Immunoblot was performed using previously described
methods [31,32]. In brief, cells were lysed in 1 × lysis
buffer (Cell signaling) or 1 × SDS loading buffer. Tumor
tissue was homogenized in 10 mM Tris–HCl (pH 7.8),
the homogenate centrifuged at 10,000 rpm for 10 min
at 4°C, and glycerol added (final concentration 15%) to
the supernatant. Protein concentration was determined
using the BCA protein assay reagent kit (Pierce, Rockford, IL). Equal amounts of protein from cell lysates or
tumor tissue homogenates were resolved by SDS-PAGE
electrophoresis. The membranes were incubated at 4°C
overnight with the following antibodies: mouse antiEZH2 (1:2,500; BD Bioscience), mouse anti-EED (1:2,000;
Millipore), mouse anti-SUZ12 [31], mouse anti-β-actin
(1:5,000; Santa Cruz). After incubation with anti-mouse
IgG horseradish peroxidase conjugated secondary antibody (1:5,000; Amersham Pharmacia Biotech), immunoreactive proteins were visualized by the enhanced
chemiluminescence reagents.
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Cell proliferation and tumor spheroid formation assays

Cells were infected with lentivirus encoding 2 individual
shEZH2s or control for 48 hrs. Cell proliferation was monitored by absorbance using the MTS assay (CellTiter 96
AQueous One Solution cell proliferation assay, Promega)
according to the manufacturer’s instruction. 2000 cells
were seeded in triplicate in a 96-well plate. At the indicated times, absorbance at 490 nm was measured in a
microplate reader.
For tumor spheroid formation, a total of 2000 single cell
suspensions were plated into 24-well ultra-low attachment
plates (Corning) and cultured in serum-free mammary epithelial growth medium (MEGM, BioWhittaker)
supplemented with B27 (Invitrogen), 20 ng/mL epidermal
growth factor (EGF), 40 ng/mL bFGF (BD Biosciences),
and 4 μg/mL heparin (Sigma) [22]. After 6 days in culture,
tumor spheroids were counted.
Cell migration and invasion assays

For cell migration assay, 48 hrs after shRNA infection,
SUM149 cells (7 × 104) were suspended in 0.5 ml of
Ham’s F-12 media and seeded onto the noncoated 8 μm
membrane of cell culture insert (BD Bioscences) in a 24
well plate with Ham’s F-12 media supplemented with
10% FBS. For matrigel invasion, the membrane of cell
culture insert was coated by adding 60 μl of 1:40 diluted
matrigel basement membrane matrix (BD Bioscences)
with Ham’s F-12 media. 1 × 105 cells were suspended in
0.5 ml of Ham’s F-12 media and plated on top of the
matrigel. After incubating 24 hrs, the cells were fixed
with 4% formaldehyde and stained with 0.5% crystal violet in PBS. The number of cells that migrated across
the membrane or invaded through the matrigel-coated
membrane was determined in 9 fields across the center
and the periphery of the membrane.
In vivo tumorigenicity

The protocol was approved by FCCC institutional animal
care and use committee (IACUC). Control or shEZH2 expressing SUM149 (3 × 106, n = 6) and FC-IBC-02S (1 ×
106, n = 4) cells were suspended in 200 μL of 1:1 ratio of
phosphate-buffered saline/matrigel (BD Biosciences) and
orthotopically injected into the mammary fat pads of six
week old female C.B-17 severe combined immunodeficient (SCID) mice. Tumor volume was calculated from
the formula TV = L*W*H*0.5236 where L, W, and H are
the tumor dimensions in three perpendicular dimensions
by caliper measurement. Mice were sacrificed 6 weeks
(SUM149) or 8 weeks (FC-IBC-02S) post inoculation. Tumors were surgically removed and weighed.
For in vivo angiogenesis assay, formalin-fixed paraffinembedded tumors from shEZH2 or control groups were
cut onto glass slides and processed for immunohistochemical (IHC) staining using previously described
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methods [31]. Purified rat anti-mouse CD31 antibody
(BD PharMingen) was used for the staining. CD31positive vessels were enumerated in randomly selected
fields.
Statistical analysis

Quantitative data were expressed as mean ± SEM. Analysis of variance (ANOVA) with Student’s t test was used
to determine the significant differences among experimental groups, and P < 0.05 was considered significant.

Results
EZH2 is expressed at higher levels in human IBC cells

EZH2 was expressed frequently in IBC tumors and predicts worse clinical outcome of IBC patients [21]. We first
sought to examine the expression of EZH2 and other essential components of PRC2 namely EED, and SUZ12 in 3
individual isolations of normal primary HME cells and 3
human IBC cell lines. The SUM149 and SUM190 cell lines
are the only available human IBC cell lines that are widely
used in IBC studies. FC-IBC-02 cell line was a newly derived IBC cell line using tumor cells from pleural effusion
fluid of a patient with metastatic secondary IBC [22]. FCIBC-02 cells were ER(−), Pgr(−) and HER2 non-amplified,
and formed tumor spheroids in suspension culture that
were strongly positive for E-cadherin, β-catenin adhesion
molecules. The tumors were developed with lung micro
metastasis when the cells were injected in the mammary
fat pad of SCID mice and recapitulated the tumor emboli
that is a signature of IBC in humans. Compared with normal HME cells, both EZH2 and SUZ12 were expressed at
significantly higher levels in all three tested human IBC cell
lines (Figure 1). Consistently, H3K27Me3, the product of
EZH2 histone H3 lysine 27 methyltransferase activity, was
also expressed at higher levels in IBC cell lines (Figure 1).
Interestingly, there was no obvious difference in EED protein expression between normal HMECs and human IBC
cell lines (Figure 1). Based on these results, we conclude
that EZH2, SUZ12, and H3K27Me3 are expressed at
higher levels in human IBC cells compared with normal
HMEC.
High tumorigenicity correlates with high expression of
EZH2 in FC-IBC-02 cells

We observed that the newly derived FC-IBC-02 tumor
cells grow as both adherent and suspension populations
when they are initially obtained from pleural effusion
fluid of the IBC patient. In addition, the suspension
population of FC-IBC-02 cells spontaneously formed
tumor spheroids, a characteristic of tumor stem/initiating cells (Figure 2A). When single cells were cultured in
suspension under low adherence conditions, adherent
cells formed less and smaller tumor spheroids compared
to suspension cells (Figure 2B), suggesting that adherent

Mu et al. Journal of Experimental & Clinical Cancer Research 2013, 32:70
http://www.jeccr.com/content/32/1/70

Page 4 of 9

to adherent cell populations (Figure 2C). Next, we orthotopically transplanted the equal numbers (2 × 106) of
adherent and suspension FC-IBC-02 cells into the mammary fat pads of mice with 5 mice in each cell population.
Tumor volume was monitored over time, and the tumor
was excised and weighed after 7 weeks. Interestingly, the
tumors were notably smaller from the transplanted adherent cell populations compared with suspension populations
(Figure 2D). Together, our results suggest that expression
levels of EZH2 positively correlates with tumor spheroid
formation and tumorigenicity in this new IBC cell line.

EZH2
SUZ12
EED
H3K27Me3
β-actin
Figure 1 EZH2 is expressed at higher levels in human IBC cell
lines. Expression of EZH2, SUZ12, EED, H3K27Me3, and β-actin in 3
indicated human IBC cell lines and 3 individual batches of primary
normal human mammary epithelial cell cultures (HMEC) was
examined by immunoblot analysis.

cells are unable to self-renew. EZH2 has been implicated
in regulating stem cell renewal, differentiation, and carcinogenesis [28,29]. Thus, we compared the expression of
EZH2 in the initial adherent and suspension populations
of FC-IBC-02 cells. Interestingly, the expression level of
EZH2 was higher in suspension cell populations compared

A

FC-IBC-02S

FC-IBC-02A

Knockdown of EZH2 inhibits the tumor spheroid formation
of human IBC cells in vitro and tumor growth in vivo

Since EZH2 was overexpressed in IBC cells and EZH2 expression positively correlates with tumor spheroid growth
and tumorigenicity in FC-IBC-02 cells, we sought to determine the effects of EZH2 knockdown on tumor spheroid
formation of IBC cells in vitro and the tumorigenicity of
IBC in vivo in an orthotopic xenograft model in immunodeficient mice. To knockdown EZH2 expression in FC-IBC02S and SUM149 cells, we used 2 individual shRNAs to the
human EZH2 gene (shEZH2). We first confirmed the
knockdown efficacy of these shEZH2s in human IBC cell
lines by immunoblotting (Figure 3A). Consistently, the level
of H3K27Me3 expression was also significantly reduced by
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Figure 2 High tumorigenicity correlates with high expression of EZH2 in FC-IBC-02 cells. A. Initial FC-IBC-02 cells obtained from pleural
effusion fluid of IBC patient growing as suspension (FC-IBC-02S) and adherent (FC-IBC-02A) populations (×200 magnification). Tumor spheroids
exhibit budding from parent to daughter spheroid in suspension culture. B. Tumor spheroid growth of FC-IBC-02S and FC-IBC-02A cells in
suspensions under ultra-low attachment culture condition for 6 days (×100 magnification). C. Expression of EZH2 in suspension and adherent
populations of FC-IBC-02 cells was examined by immunoblot. D. Growth of FC-IBC-02 adherent (2 × 106) and suspension (2 × 106) cells in vivo in
SCID mice. Tumor volume was monitored over time, and the tumor was excised and weighed after 7 weeks. *, P < 0.001 compared to FC-IBC-02A
at week 7.
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shEZH2 in both cell lines (Figure 3A). We compared the
cell growth of control and shEZH2-infected IBC cells using
the MTS assay. Compared with controls, EZH2 knockdown
significantly suppressed the growth of human IBC cells
(Figure 3C and D). We observed the growth inhibition by
two individual shEZH2s, suggesting that the observed effects are likely not due to off-target effects. In addition,
shEZH2 suppressed the growth of both SUM149 (Figure 3C)
and FC-IBC-02S (Figure 3D) IBC cell lines, suggesting
that the observed effects are not cell line specific. Importantly, we showed EZH2 knockdown significantly suppressed the tumor spheroid formation of FC-IBC-02S cells
in suspension culture under ultra-low attachment culture
condition, which is a characteristic of IBC cancer stem
cells (Figure 3B). Based on these results, we conclude that
knockdown of EZH2 suppresses the proliferation and
tumor spheroid growth of human IBC cells in vitro.
We next sought to determine the effects of EZH2 knockdown on the tumorigenicity of human IBC cells in vivo in

A
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an orthotopic xenograft model in immunodeficient mice.
Toward this goal, control and shEZH2-expressing FC-IBC02S and SUM149 cells were orthotopically transplanted into
the mammary fat pads of immunodeficient mice. Compared
with controls, shEZH2 significantly suppressed the growth
of xenografted human IBC cells in immunodeficient mice.
Similar suppression of tumor growth by shEZH2 was observed for both xenografted FC-IBC-02S (Figure 4A and C)
and SUM149 (Figure 4B and D) IBC cells, suggesting that
the observed effects are not cell line specific. We confirmed
the EZH2 knockdown in dissected tumors by immunoblotting (Figure 4E and F). Together, we conclude that
EZH2 knockdown significantly inhibits the growth of human IBC cells in vivo in orthotopic xenograft IBC models.
EZH2 knockdown inhibits the invasion and tumor
angiogenesis of human IBC cells

EZH2 has been implicated in regulating invasion of
breast cancer cells [15]. Thus, we sought to determine

C
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------FC-IBC-02S------ --------SUM149--------

B

Control

shEZH2 1

Cell growth (relative units)
MTS assay

EZH2

shEZH2 2

control
shEZH2 1
shEZH2 2

1.6
1.4
1.2

*
*

1
0.8
0.6
0.4
0.2
0
0

3

4
Days

5

6

Day 3

D
1.4
Cell growth (relative units)
MTS assay

Day 6

180

Number of spheroids

160

Control

140
120

100

40

1
0.8

*
*

0.6
0.4
0.2
0
0

80
60

control
shEZH2 1
shEZH2 2

1.2

shEZH2 1

*

3

4
Days

5

6

shEZH2 2

*

20
0

Figure 3 EZH2 knockdown inhibits the cell growth of SUM149 and FC-IBC-02S cells and tumor spheroid formation of FC-IBC-02S cells.
A. SUM149 and FC-IBC-02S cells were infected with 2 individual lentivirus encoded shEZH2 or control. Expression of EZH2, H3K27Me3, H3K9Me3,
and histone H3 was examined in drug-selected cells by western blotting. B. Same as A, 2000 of control or shEZH2 expressing FC-IBC-02S single
cells were cultured in suspension in ultra-low attachment plates. After culturing 6 days, the number of tumor spheroids was counted. Mean of 3
independent experiments with SEM. *, P < 0.001 compared to control. C and D. Same as A, but 2 × 103 of drug-selected cells were seeded and
assayed by MTS in SUM149 (C) and FC-IBC-02S (D) cells at indicated time points. Mean of 3 independent experiments with SEM. *, P < 0.01
compared to control.
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the effects of EZH2 knockdown on the invasion of human
IBC cells. Toward this goal, we tested the ability of human
IBC cells infected with control or shEZH2-encoding lentivirus migrating through uncoated membrane or invading
through matrigel-coated membrane using a Boydenchamber invasion assay. Compared with controls, EZH2
knockdown significantly inhibited the migration and invasion of SUM149 cells (Figure 5A and B). We conclude that
EZH2 knockdown inhibits the migration and invasion of
human IBC cells. Interestingly, EZH2 knockdown tumors
showed less blood vessels compared with control tumors
(Figure 4A and B). To examine the reduced angiogenesis,
we immunostained tumor sections from xenografted FCIBC-02S with CD31, a marker used to quantitate vessel
density. Compared with control tumors, EZH2 knockdown tumors displayed a significant reduction in CD31positive vessels (Figure 5C). These results suggest that
EZH2 knockdown inhibits tumor angiogenesis, and subsequently inhibits tumor growth.

C

A
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Discussion
The major finding of this study is that the EZH2 knockdown significantly suppressed the formation of tumor
spheroids in vitro (a characteristic of IBC cancer stem
cells), and tumor growth in vivo in a new human IBC
model. New FC-IBC-02 cell line is the first to be used in
studying the functional role of EZH2, although the negative effects of silencing of EZH2 on cell growth have
been shown in some breast cancer cell lines including
SUM149 cells.
We have recently shown that EZH2 is often expressed
in IBC tumors and is associated not only with unfavorable prognostic variables but also with significantly
worsening survival [21]. Consistent with previous findings, EZH2 was overexpressed in human IBC cell lines.
These findings suggest that clinical outcomes of IBC patients can be stratified on the basis of EZH2 status. We
further examined the function of EZH2 in SUM149 cells
and a new IBC cell line-FC-IBC-02 derived from pleural
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Figure 4 EZH2 knockdown inhibits the growth of SUM149 and FC-IBC-02S cells in vivo in SCID mice. A and B. Control or shEZH2
expressing FC-IBC-02S (1 × 106) and SUM149 (3 × 106) cells were orthotopically transplanted into the mammary fat pads of SCID mice.
Nine weeks (FC-IBC-02S cells) and six weeks (SUM149 cells) post injection, tumors were removed from mice and imaged. C (FC-IBC-02S) and
D (SUN149) cells, tumor size was measured by caliper measurements. Data shown represent mean tumor volume with SEM, p value compared
with control. E (FC-IBC-02S) and F (SUN149), western blot assay of EZH2 expression from pooled FC-IBC-02S and SUM149 xenografted tumors.
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Figure 5 EZH2 knockdown suppresses the invasion and tumor angiogenesis of human IBC cells. A. Control and shEZH2 expressing
SUM149 cells at equal number were seeded onto the noncoated membrane (migration) and matrigel-coated membrane (invasion). After
incubating 24 hrs, the cells migrated through both uncoated and matrigel-coated membrane were stained with 0.05% crystal violet in PBS.
B. Quantitation of A, relative percentage of shEZH2 expressing cells migrated through uncoated membrane or invaded through matrigel-coated
membrane compared to controls was indicated. Mean of 3 independent experiments with SEM. *, P < 0.05 compared to control. C. Tumor tissues
from FC-IBC-02S xenografts were stained with anti-CD31 antibody to measure microvessel density (×100 magnification). The CD31-positive
microvessels are marked (arrows). Quantitation of CD31 vessel staining is shown in the bottom graph. *, P < 0.01 compared to control.

effusion fluid of an IBC patient. A very recent study
showed that SUM149 cell line might not be IBC-specific
from gene expression data [33]. FC-IBC-02 cell line,
however, is a more representative model for the IBC
studies [22]. The treatment options for IBC patients,
particularly for triple-negative IBC are very limited at
present, while the results of this study indicate that
EZH2 is a putative target for developing a new treatment
for this devastating disease.
The mechanism of EZH2 promoting IBC remains to be
elucidated. With IBC human cell lines in this study, we
showed that both EZH2 and H3K27Me3 are expressed at
higher levels compared to cultured normal HME cells
(Figure 1). EZH2 catalyzes trimethylation of lysine 27 on
histone 3, an epigenetic label mediating gene silencing,
while the correlation between H3K27Me3 expression and
clinical outcome is inconsistent. A very recent study
showed that there was a significantly different expression
of both EZH2 and H3K27Me3 in different subtypes of
breast tumor [34]. High abundance of EZH2 was detected

in basal-like, triple-negative and HER2-enriched tumors,
but high H3K27Me3 was found mainly in luminal A,
HER2-enriched and normal-like tumors. Further studies
are warranted to determine the role of H3K27Me3 expression in IBC tumors.
Although there are few cell lines currently available to
evaluate the biology of IBC, there is no good model
available for CSC studies in IBC. The majority of IBC
studies have been performed using the cell lines
SUM149 and SUM 190, both of which were developed
from the primary tumor of IBC patients [10]. Only the
Mary-X and the WIBC-9 in vivo xenograft models are
available to recapitulate the tumor emboli that are the
signature of IBC in humans, but none of them can be
successfully passaged or propagated long term in vitro
cultures [35,36]. Our recent studies have shown that
new developed FC-IBC-02 cells can be successfully passaged under both adherent and suspension culture conditions [22]. This new IBC model could be a more
representative model for the further IBC studies since
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FC-IBC-02 cells were able to develop tumor with the
presence of tumor emboli and metastasis in SCID mice.
In this study, we are interested in studying the functional
role of EZH2 in this new IBC model. We observed that
newly derived FC-IBC-02 suspension cell population
formed tumor spheroids, a characteristic of CSC and
expressed a higher level of EZH2 and generated larger
tumor in size compared to initial adherent cell population when transplanted into the mammary fat pads of
SCID mice (Figure 2D). Notably, knockdown of EZH2
significantly inhibits the tumor spheroid growth of human IBC cells in vitro. Recent studies showed that CSC
population may be responsible for resistance to chemotherapy, radiation therapy and contribute to relapse following the treatment [25-27,37,38]. This suggests that
more effective therapies will require the successful
targeting of the CSCs population. We believe that the
FC-IBC-02 cell line described in this study could serve
as a potential model for CSC studies in human IBC. The
findings of this study provide evidence that EZH2 is a
potential target for the self-renewal of IBC cells.
Angiogenesis is required for invasive tumor growth
and metastasis. A recent study showed that EZH2
is a key regulator of tumor angiogenesis through its
expression in cancer associated endothelial cells in human ovarian cancer [39]. Interestingly, we observed a
visible evidence for the loss of angiogenesis in the EZH2
knockdown tumors (Figure 4A and B). In addition, there
was a significant reduction in CD31-positive vessels in
EZH2 knockdown tumors compared to control tumors
(Figure 5C), suggesting that the loss of angiogenesis subsequently inhibits tumor growth. The mechanisms implicated in the angiogenesis role of EZH2 in IBC need
further investigation. Several specific inhibitors of
EZH2’s methyltransferase activity have been reported
[40-42]. Our recent studies have shown that the threedimensional culture sensitizes epithelial ovarian cancer
cells to EZH2 methyltransferase inhibition, which suppresses cell growth, induces apoptosis and inhibits invasion [43]. Further studies are warranted to examine the
effects of these specific inhibitors of EZH2 on the characteristics of IBC, such as homotypic aggregation of
tumor emboli, invasion and metastasis of IBCs.

Conclusions
EZH2 are overexpressed in human IBC cell lines. EZH2 is
critical for the formation of tumor spheroids and invasion
of human IBC cells and could be a potential target for developing novel therapeutic strategies for human IBC.
Abbreviations
IBC: Inflammatory breast cancer; EZH2: Enhancer of zeste homolog 2;
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stem cell.

Page 8 of 9

Competing interests
All other authors declare no competing interests.
Authors’ contributions
ZM and HL performed all the experiments, analyzed the data and drafted
the manuscript. SF assisted with in vivo experiments. KA assisted with
establishing IBC cell line. MC and RZ conceived of the study, reviewed and
finalized the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This publication was supported in part by American Airlines-Komen For the
Cure Foundation Promise Grant to MC and by an NIH/NCI R01CA163377
to R.Z.
Author details
1
Department of Medical Oncology, Thomas Jefferson University; and Kimmel
Cancer Center, Philadelphia, PA 19107, USA. 2Department of Medical
Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. 3Wistar
Institute, Philadelphia, PA 19104, USA.
Received: 28 August 2013 Accepted: 24 September 2013
Published: 27 September 2013
References
1. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH: Trends in
inflammatory breast carcinoma incidence and survival: the surveillance,
epidemiology, and end results program at the National Cancer Institute.
J Natl Cancer Inst 2005, 97(13):966–975.
2. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA,
Dirix LY, Levine PH, Lucci A, Krishnamurthy S, et al: International expert
panel on inflammatory breast cancer: consensus statement for
standardized diagnosis and treatment. Ann Oncol 2011, 22(3):515–523.
3. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: a
review. J Clin Oncol 1992, 10(6):1014–1024.
4. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo
AM, Sneige N, Islam R, Ueno NT, Buchholz TA, et al: Inflammatory breast
cancer (IBC) and patterns of recurrence: understanding the biology of a
unique disease. Cancer 2007, 110(7):1436–1444.
5. Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH: Cooperative role of Ecadherin and sialyl-Lewis X/A-deficient MUC1 in the passive
dissemination of tumor emboli in inflammatory breast carcinoma.
Oncogene 2002, 21(22):3631–3643.
6. Dawood S, Cristofanilli M: Inflammatory breast cancer: what progress
have we made? Oncology 2011, 25(3):264–270.
7. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P,
Lucci A, Singh B, Hung MC, Hortobagyi GN, et al: Epidermal growth factor
receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial
phenotype and inhibits metastasis in inflammatory breast cancer.
Clin Cancer Res 2009, 15(21):6639–6648.
8. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, GonzalezAngulo AM, Morandi P, Bucana C, Hortobagyi GN, et al: Expression of
growth factor and chemokine receptors: new insights in the biology of
inflammatory breast cancer. Ann Oncol 2007, 18(6):1021–1029.
9. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT:
Molecular targets for treatment of inflammatory breast cancer.
Nat Rev Clin Oncol 2009, 6(7):387–394.
10. Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van
Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY: Identification
of cell-of-origin breast tumor subtypes in inflammatory breast cancer by
gene expression profiling. Breast Cancer Res Treat 2006, 95(3):243–255.
11. Cao R, Zhang Y: SUZ12 is required for both the histone methyltransferase
activity and the silencing function of the EED-EZH2 complex. Mol Cell
2004, 15(1):57–67.
12. Chang CJ, Hung MC: The role of EZH2 in tumour progression. Br J Cancer
2012, 106(2):243–247.
13. Sauvageau M, Sauvageau G: Polycomb group proteins: multi-faceted
regulators of somatic stem cells and cancer. Cell Stem Cell 2010,
7(3):299–313.
14. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP,
Akslen LA: Expression of enhancer of zeste homologue 2 is significantly

Mu et al. Journal of Experimental & Clinical Cancer Research 2013, 32:70
http://www.jeccr.com/content/32/1/70

15.

16.

17.

18.
19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

associated with increased tumor cell proliferation and is a marker of
aggressive breast cancer. Clin Cancer Res 2006, 12(4):1168–1174.
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt
RG, Otte AP, Hayes DF, et al: EZH2 is a marker of aggressive breast cancer
and promotes neoplastic transformation of breast epithelial cells.
Proc Natl Acad Sci U S A 2003, 100(20):11606–11611.
Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H,
Packeisen J, Sewalt RA, Otte AP, van Diest PJ: Poorly differentiated breast
carcinoma is associated with increased expression of the human
polycomb group EZH2 gene. Neoplasia 2003, 5(6):481–488.
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas
SA, Salvesen HB, Otte AP, Akslen LA: EZH2 expression is associated with
high proliferation rate and aggressive tumor subgroups in cutaneous
melanoma and cancers of the endometrium, prostate, and breast.
J Clin Oncol 2006, 24(2):268–273.
Ding L, Kleer CG: Enhancer of Zeste 2 as a marker of preneoplastic
progression in the breast. Cancer Res 2006, 66(19):9352–9355.
Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M,
Merajver SD, Kleer CG: Downregulation of EZH2 decreases growth of
estrogen receptor-negative invasive breast carcinoma and requires
BRCA1. Oncogene 2009, 28(6):843–853.
Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A,
Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen
M: EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation
in breast cancer. Breast Cancer Res 2008, 10(6):R109.
Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA,
Valero V, Cristofanilli M: Polycomb group protein EZH2 is frequently
expressed in inflammatory breast cancer and is predictive of worse
clinical outcome. Cancer 2011, 117(24):5476–5484.
Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K,
Alpaugh RK, Huang Y, Cao Y, Ye Z, et al: Inflammatory breast cancer (IBC):
clues for targeted therapies. Breast Cancer Res Treat 2013, 140(1):23–33.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF:
Prospective identification of tumorigenic breast cancer cells.
Proc Natl Acad Sci U S A 2003, 100(7):3983–3988.
Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS: Stem cells in
normal breast development and breast cancer. Cell Prolif 2003,
36(Suppl 1):59–72.
Phillips TM, McBride WH, Pajonk F: The response of CD24(−/low)/CD44+
breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006,
98(24):1777–1785.
Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ,
Lee EY: Cancer stem cells contribute to cisplatin resistance in Brca1/p53mediated mouse mammary tumors. Cancer Res 2008, 68(9):3243–3250.
Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J,
Clouthier SG, Wicha MS: Regulation of mammary stem/progenitor cells by
PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7(6):e1000121.
Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu
JM, Hortobagyi GN, Hung MC: EZH2 promotes expansion of breast tumor
initiating cells through activation of RAF1-beta-catenin signaling.
Cancer Cell 2011, 19(1):86–100.
Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ,
Mongan NP: Regulation of stem cell pluripotency and differentiation
involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2
pluripotency transcription factors with polycomb repressive complexes
and stem cell microRNAs. Stem Cells Dev 2009, 18(7):1093–1108.
Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B,
Slater C, Zhou Y, Daly M, et al: Altered gene expression in morphologically
normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2
mutations. Cancer Prev Res 2010, 3(1):48–61.
Li H, Cai Q, Godwin AK, Zhang R: Enhancer of zeste homolog 2 promotes
the proliferation and invasion of epithelial ovarian cancer cells.
Mol Cancer Res 2010, 8(12):1610–1618.
Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon AL, Agrawal S,
Pollack A: Antisense MDM2 enhances the response of androgen
insensitive human prostate cancer cells to androgen deprivation in vitro
and in vivo. Prostate 2008, 68(6):599–609.
Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Robertson FM,
Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, et al: Uncovering the
molecular secrets of Inflammatory Breast Cancer biology: An integrated

Page 9 of 9

34.

35.
36.

37.

38.

39.

40.

41.

42.

43.

analysis of three distinct Affymetrix gene expression data sets.
Clin Cancer Res 2013, 19(17):4685–4696.
Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal
LH, Ethier SP, Bendahl PO, Stal O, et al: Global H3K27 trimethylation and
EZH2 abundance in breast tumor subtypes. Mol Oncol 2012, 6(5):494–506.
Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH: A novel human xenograft
model of inflammatory breast cancer. Cancer Res 1999, 59(20):5079–5084.
Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi
F, Yoshimoto M, Iwanaga T, et al: Absence of endothelial cells, central
necrosis, and fibrosis are associated with aggressive inflammatory breast
cancer. Cancer Res 2001, 61(2):445–451.
Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S: Emerging
role of cancer stem cells in the biology and treatment of ovarian cancer:
basic knowledge and therapeutic possibilities for an innovative
approach. J Exp Clin Cancer Res 2013, 32:48. doi: 10.1186/1756-9966.
Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou W, Qi X, Pei Y, Zhu X, Zhao Z,
Yang L: Compound Kushen Injection suppresses human breast cancer
stem-like cells by down-regulating the canonical Wnt/β-catenin
pathway. J Exp Clin Cancer Res 2011, 30:103. 10.1186/1756-9966.
Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena
GN, Hu W, Stone RL, Munkarah A, et al: Regulation of tumor angiogenesis
by EZH2. Cancer Cell 2010, 18(2):185–197.
Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, et al:
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells
proliferation. Proc Natl Acad Sci U S A 2012, 109(52):21360–21365.
Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD,
Raimondi A, Majer CR, Song J, et al: A selective inhibitor of EZH2 blocks
H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012,
8(11):890–896.
McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y,
Graves AP, Della Pietra A 3rd, Diaz E, et al: EZH2 inhibition as a therapeutic
strategy for lymphoma with EZH2-activating mutations. Nature 2012,
492(7427):108–112.
Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R:
Three-dimensional culture sensitizes epithelial ovarian cancer cells to
EZH2 methyltransferase inhibition. Cell Cycle 2013, 12(13):2113–2119.

doi:10.1186/1756-9966-32-70
Cite this article as: Mu et al.: EZH2 knockdown suppresses the growth
and invasion of human inflammatory breast cancer cells. Journal of
Experimental & Clinical Cancer Research 2013 32:70.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

